Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

15 trials with published results (14%)

Research Maturity

72 completed trials (65% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.7%

3 terminated out of 110 trials

Success Rate

96.0%

+9.4% vs benchmark

Late-Stage Pipeline

19%

21 trials in Phase 3/4

Results Transparency

21%

15 of 72 completed with results

Key Signals

15 with results96% success

Data Visualizations

Phase Distribution

82Total
Not Applicable (29)
Early P 1 (1)
P 1 (10)
P 2 (21)
P 3 (11)
P 4 (10)

Trial Status

Completed72
Unknown17
Withdrawn5
Recruiting5
Terminated3
Enrolling By Invitation3

Trial Success Rate

96.0%

Benchmark: 86.6%

Based on 72 completed trials

Clinical Trials (110)

Showing 20 of 20 trials
NCT02767973Not ApplicableSuspended

To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility

NCT07694947Not ApplicableCompletedPrimary

Changes in Eosinophil Cationic Protein and Sputum Eosinophils Following Allergen Immunotherapy

NCT04699604Phase 3CompletedPrimary

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

NCT06438757Phase 2CompletedPrimary

Trial of JYB1904 in Patients With Allergic Asthma

NCT01536522Early Phase 1Enrolling By Invitation

Asthma Inflammation Research

NCT07055542Not ApplicableRecruitingPrimary

Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

NCT06960382Phase 1Recruiting

Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma

NCT07425639Recruiting

ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar

NCT05186025Active Not Recruiting

Tyrosine Allergoid Paediatric and Adult Study

NCT07352488Not ApplicableNot Yet RecruitingPrimary

Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome

NCT07342803Phase 2RecruitingPrimary

Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

NCT05008965Phase 2RecruitingPrimary

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

NCT06592768Phase 1TerminatedPrimary

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

NCT05191186Phase 3Completed

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy

NCT07114133Not ApplicableEnrolling By Invitation

A Study on the Efficacy of Environmental Probiotics in Patients With Cat Hair Allergies

NCT05297760Phase 1Completed

Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract

NCT06486662Phase 1CompletedPrimary

A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients

NCT06771934Active Not RecruitingPrimary

Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma

NCT06267261Not ApplicableCompletedPrimary

Efficacy of Face Mask in Reducing Respiratory Allergic Symptoms in Birch-allergic Subjects in ALYATEC Exposure Chamber

NCT06494345Phase 1CompletedPrimary

A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers

Scroll to load more

Research Network

Activity Timeline